PMV Pharmaceuticals, Inc. (PMVP)

Market Cap	69.62M
Revenue (ttm)	n/a
Net Income (ttm)	-60.88M
Shares Out	51.95M
EPS (ttm)	-1.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	444,712
Open	1.265
Previous Close	1.260
Day's Range	1.265 - 1.350
52-Week Range	0.810 - 1.820
Beta	1.49
Analysts	Strong Buy
Price Target	5.00 (+273.13%)
Earnings Date	Aug 7, 2025

About PMVP

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It’s lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is base...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 25, 2020
• Employees: 47
• Stock Exchange: NASDAQ
• Ticker Symbol: PMVP
• Website: https://www.pmvpharma.com

Analyst Summary

According to one analyst, the rating for PMVP stock is "Strong Buy" and the 12-month stock price target is $5.0.

Price Target

$5.0

(273.13% upside)

Analyst Consensus: Strong Buy